Uroplasty (UPI) and The Competition Head-To-Head Survey
Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare Uroplasty to related companies based on the strength of its earnings, institutional ownership, risk, profitability, analyst recommendations, dividends and valuation.
Risk and Volatility
Uroplasty has a beta of -1.26, suggesting that its stock price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s rivals have a beta of 0.95, suggesting that their average stock price is 6% less volatile than the S&P 500.
This table compares Uroplasty and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Uroplasty and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Uroplasty Competitors||$1.67 billion||$207.58 million||82.51|
Uroplasty’s rivals have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and price targets for Uroplasty and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Medical Devices & Implants” companies have a potential upside of 38.01%. Given Uroplasty’s rivals higher probable upside, analysts plainly believe Uroplasty has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Uroplasty rivals beat Uroplasty on 6 of the 8 factors compared.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.